All In Biotech

Free tool

FAERS Monitor: Simlandi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761299 or its brand name (Simlandi, Adalimumab-Ryvk). Reports on generic versions are filed under their own applications.

Reports

1,090

Serious

876

80% of reports

Hospitalization

276

Death reported

78

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use149
  • product dose omission issue135
  • crohn^s disease127
  • pain103
  • drug ineffective99
  • inappropriate schedule of product administration99
  • rheumatoid arthritis91
  • arthralgia87
  • fatigue87
  • diarrhoea81
  • death74
  • headache68
  • abdominal pain63
  • hospitalisation50
  • malaise50

Reports by year received

View as table
YearReports
20191
20221
20234
2024245
2025358
2026481

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,069 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
rheumatoid arthritisSignal9115.512.71,224
inappropriate schedule of product administrationSignal9910.68.8859
product dose omission issueSignal1358.97.6947
hospitalisationSignal506.34.8218
abdominal painSignal635.24.1213
arthralgiaSignal874.03.3200
off label useSignal1493.32.8245
painSignal1033.22.7162
diarrhoeaSignal812.42.068
malaiseSignal502.21.732
fatigueSignal872.21.855
headacheSignal682.11.739
death741.71.319
drug ineffective991.41.214
crohn^s disease1270.00.02,433,709

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.